Syntex' Toradol Oral approved
Executive Summary
Oral ketorolac tromethamine non-narcotic nonsteroidal anti- inflammatory drug approved by FDA "for limited duration use, as needed, for the management of pain," Syntex announces Dec. 20. Toradol Oral is not recommended for chronic use due to the incidence of adverse gastrointestinal events that increases with prolonged use, Syntex notes. Toradol Oral is expected to be available in March 1992, and Syntex "expects to have an agreement signed in the near future with a marketing partner." Toradol IM injectable, approved in May 1990, is comarketed in the U.S. by Roche. The oral ketorolac could be used as a followup therapy for patients who have received the injectable form of the drug.